LakeShore Biopharma (LSB) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

LSB · Stock Price

USD 0.63+0.00 (+0.00%)

Historical price data

Overview

LakeShore Biopharma (LSB) is a China-based, publicly traded biotech focused on oncology and autoimmune disorders. The company employs a portfolio-centric strategy, advancing a pipeline of monoclonal antibodies, ADCs, and small molecules through clinical development. Its core competency lies in identifying, in-licensing, and developing therapeutic candidates, aiming to deliver novel treatments in markets with high unmet need.

OncologyAutoimmune Diseases

Technology Platform

LakeShore employs an asset-centric development platform, focusing on strategic in-licensing and clinical development of diverse therapeutic modalities rather than a single proprietary technology.

Opportunities

The significant unmet medical need in oncology and autoimmune diseases within China's large and growing pharmaceutical market presents a major opportunity.

Success with its lead LAG-3 inhibitor could position LakeShore as an attractive partner for global biopharma companies seeking a foothold in China.

Risk Factors

High clinical trial failure risk, intense competition in core therapeutic areas, and potential difficulty in raising sufficient capital given its low public market valuation and liquidity are the primary risks.

Competitive Landscape

LakeShore faces intense competition from global pharmaceutical giants with approved LAG-3 therapies and deep pipelines, as well as from a crowded field of innovative Chinese biotechs vying for market share and partnership deals.

More companies in Antibody-Drug Conjugates →More companies in China →